Onconetix (ONCO) Projected to Announce Earnings on Thursday

Onconetix (NASDAQ:ONCO) is expected to issue its Q3 2026 resultson Thursday, November 12th. Analysts expect Onconetix to announce earnings of ($45,050.00) per share and revenue of $0.02 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Onconetix (NASDAQ:ONCO) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($12.80) earnings per share for the quarter, beating the consensus estimate of ($45,050.00) by $45,037.20. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million.

Onconetix Stock Performance

Shares of NASDAQ:ONCO opened at $3.58 on Tuesday. Onconetix has a 52-week low of $3.34 and a 52-week high of $1,610.00. The business has a 50-day moving average price of $6.51 and a 200-day moving average price of $125.90.

Analyst Ratings Changes

Several equities analysts recently weighed in on ONCO shares. Weiss Ratings upgraded shares of Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, October 29th. Wall Street Zen raised shares of Onconetix from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Onconetix Company Profile

Onconetix, Inc is a biotechnology company focused on developing and commercializing diagnostic and therapeutic products for men’s health. The company’s portfolio is centered primarily on prostate health, with products intended to support the detection, risk assessment and treatment of prostate-related conditions.

Its lead diagnostic product is Proclarix, a blood-based test designed to help assess the risk of clinically significant prostate cancer in men with elevated prostate-specific antigen (PSA) levels.